Anti-tumor monoclonal antibodies in conjunction with β-glucans: A novel anti-cancer immunotherapy

Current Medicinal Chemistry

Volumn 19, Issue 25, 2012, Pages 4298-4305

  Xiang, D ^a,b   Sharma, V R ^a   Freter, C E ^b   Yan, J ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Glucans; ADCC; Cancer immunotherapy; Complement; CR3; Leukocytes; mAb; Macrophages; Neutrophils; Targeted therapy

Indexed keywords

BETA GLUCAN; BEVACIZUMAB; CETUXIMAB; COMPLEMENT COMPONENT C3 RECEPTOR; IRINOTECAN; LECTIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; RITUXIMAB; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; NONHUMAN; PATIENT CARE; REVIEW; SJOEGREN SYNDROME; STOMACH CANCER; XENOGRAFT; YEAST;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BETA-GLUCANS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84866701494     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802884303     Document Type: Review

References (106)

1. Encyclopædia Britannica. Encyclopædia Britannica Online: Edward Jenner. http://www.britannica.com/EBchecked/topic/302579/Edward-Jenner.
2. Weiner, L. M.; Murray, J. C.; Shuptrine, C. W. Antibody-based immunotherapy of cancer. Cell, 2012, 148, 1081-1084.
3. Habermann, T. M.; Weller, E. A.; Morrison, V. A.; Gascoyne, R. D.; Cassileth, P. A.; Cohn, J. B.; Dakhil, S. R.; Woda, B.; Fisher, R. I.; Peterson, B. A.; Horning, S. J. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24, 3121-3127.
4. Feugier, P.; Van Hoof, A.; Sebban, C.; Solal-Celigny, P.; Bouabdallah, R.; Ferme, C.; Christian, B.; Lepage, E.; Tilly, H.; Morschhauser, F.; Gaulard, P.; Salles, G.; Bosly, A.; Gisselbrecht, C.; Reyes, F.; Coiffier, B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 2005, 23, 4117-4126.
5. US Food and Drug Administration: Rituxan Label http://www.accessdata. fda.gov/DRUGSATFDA-DOCS/LABEL/2011/103705S5332LBL.PDF.
6. Godeau, B.; Porcher, R.; Fain, O.; Lefrere, F.; Fenaux, P.; Cheze, S.; Vekhoff, A.; Chauveheid, M. P.; Stirnemann, J.; Galicier, L.; Bourgeois, E.; Haiat, S.; Varet, B.; Leporrier, M.; Papo, T.; Khellaf, M.; Michel, M.; Bierling, P. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, 2008, 112, 999-1004.
7. Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer, C. E., Jr.; Davidson, N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A.; Swain, S. M.; Pisansky, T. M.; Fehrenbacher, L.; Kutteh, L. A.; Vogel, V. G.; Visscher, D. W.; Yothers, G.; Jenkins, R. B.; Brown, A. M.; Dakhil, S. R.; Mamounas, E. P.; Lingle, W. L.; Klein, P. M.; Ingle, J. N.; Wolmark, N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353, 1673-1684.
8. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344, 783-792.
9. Giantonio, B. J.; Catalano, P. J.; Meropol, N. J.; O'Dwyer, P. J.; Mitchell, E. P.; Alberts, S. R.; Schwartz, M. A.; Benson, A. B., 3rd Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 2007, 25, 1539-1544.
10. Hochster, H. S.; Hart, L. L.; Ramanathan, R. K.; Childs, B. H.; Hainsworth, J. D.; Cohn, A. L.; Wong, L.; Fehrenbacher, L.; Abubakr, Y.; Saif, M. W.; Schwartzberg, L.; Hedrick, E. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol, 2008, 26, 3523-3529.
11. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355, 2542-2550.
12. Tabernero, J.; Van Cutsem, E.; Diaz-Rubio, E.; Cervantes, A.; Humblet, Y.; Andre, T.; Van Laethem, J. L.; Soulie, P.; Casado, E.; Verslype, C.; Valera, J. S.; Tortora, G.; Ciardiello, F.; Kisker, O.; de Gramont, A. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2007, 25, 5225-5232.
13. Moosmann, N.; Heinemann, V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther, 2007, 7, 243-256.
14. Jonker, D. J.; O'Callaghan, C. J.; Karapetis, C. S.; Zalcberg, J. R.; Tu, D.; Au, H. J.; Berry, S. R.; Krahn, M.; Price, T.; Simes, R. J.; Tebbutt, N. C.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M. J. Cetuximab for the treatment of colorectal cancer. N Engl J Med, 2007, 357, 2040-2048.
15. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 2006, 354, 567-578.
16. Vermorken, J. B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H. R.; Cupissol, D.; Peyrade, F.; Benasso, M.; Vynnychenko, I.; De Raucourt, D.; Bokemeyer, C.; Schueler, A.; Amellal, N.; Hitt, R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008, 359, 1116-1127.
17. Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 2002, 7 Suppl 4, 2-8.
18. Jain, R. K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol, 2002, 29, 3-9.
19. Shan, D.; Ledbetter, J. A.; Press, O. W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother, 2000, 48, 673-683.
20. Wang, S. Y.; Weiner, G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther, 2008, 8, 759-768.
21. US FOOD AND DRUG ADMINISTRATION: Vectibix®(panitumumab) http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125147s080lbl.p df.
22. US FOOD AND DRUG ADMINISTRATION: ARZERRA (ofatumumab) http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125326lbl.pdf.
23. Li, B.; Shi, S.; Qian, W.; Zhao, L.; Zhang, D.; Hou, S.; Zheng, L.; Dai, J.; Zhao, J.; Wang, H.; Guo, Y. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res, 2008, 68, 2400-2408.
24. Goldsmith, S. J. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med, 2010, 40, 122-135.
25. Song, H.; Sgouros, G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv, 2011, 8, 26-44.
26. Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, S.; Tibbitts, J.; Yi, J. H.; Sliwkowski, M. X.; Jacobson, F.; Lutzker, S. G.; Burris, H. A. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol, 2010, 28, 2698-2704.
27. Perez E, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Ng V, Linehan C, Agresta S, Hurvitz S. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g) ESMO 2010; Abstract LBA3.
28. Burris, H. A., 3rd; Tibbitts, J.; Holden, S. N.; Sliwkowski, M. X.; Lewis Phillips, G. D. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer, 2011, 11, 275-282.
29. Burris, H. A. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther, 2011, 11, 807-819.
30. Junttila, T. T.; Tanner, M.; Isola, J. [Targeted cytotoxic drugs emerging for cancer therapy]. Duodecim, 2011, 127, 343-349.
31. Ricart, A. D. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther, 2011, 89, 513-523.
32. Hong, F.; Hansen, R. D.; Yan, J.; Allendorf, D. J.; Baran, J. T.; Ostroff, G. R.; Ross, G. D. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res, 2003, 63, 9023-9031.
33. Hong, F.; Yan, J.; Baran, J. T.; Allendorf, D. J.; Hansen, R. D.; Ostroff, G. R.; Xing, P. X.; Cheung, N. K.; Ross, G. D. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol, 2004, 173, 797-806.
34. Yan, J.; Vetvicka, V.; Xia, Y.; Coxon, A.; Carroll, M. C.; Mayadas, T. N.; Ross, G. D. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol, 1999, 163, 3045-3052.
35. Cheung, N. K.; Modak, S. Oral (1->3), (1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res, 2002, 8, 1217-1223.
36. Cheung, N. K.; Modak, S.; Vickers, A.; Knuckles, B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother, 2002, 51, 557-564.
37. Modak, S.; Koehne, G.; Vickers, A.; O'Reilly, R. J.; Cheung, N. K. Rituximab therapy of lymphoma is enhanced by orally administered (1->3), (1->4)-D-beta-glucan. Leuk Res, 2005, 29, 679-683.
38. Li, B.; Allendorf, D. J.; Hansen, R.; Marroquin, J.; Cramer, D. E.; Harris, C. L.; Yan, J. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res, 2007, 67, 7421-7430.
39. Salvador, C.; Li, B.; Hansen, R.; Cramer, D. E.; Kong, M.; Yan, J. Yeastderived beta-glucan augments the therapeutic efficacy mediated by antivascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res, 2008, 14, 1239-1247.
40. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256, 495-497.
41. Maloney, D. G.; Liles, T. M.; Czerwinski, D. K.; Waldichuk, C.; Rosenberg, J.; Grillo-Lopez, A.; Levy, R. Phase I clinical trial using escalating singledose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 1994, 84, 2457-2466.
42. Reff, M. E.; Carner, K.; Chambers, K. S.; Chinn, P. C.; Leonard, J. E.; Raab, R.; Newman, R. A.; Hanna, N.; Anderson, D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994, 83, 435-445.
43. McLaughlin, P.; Grillo-Lopez, A. J.; Link, B. K.; Levy, R.; Czuczman, M. S.; Williams, M. E.; Heyman, M. R.; Bence-Bruckler, I.; White, C. A.; Cabanillas, F.; Jain, V.; Ho, A. D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 1998, 16, 2825-2833.
44. Robak, T.;Moiseev, S.I.;Dmoszynska, A.; et al. Rituximab, Fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the International Randomized Phase III REACH Trial. Blood. ASH Annual Meeting Abstracts 2008;112(11):lba-1.
45. Hallek, M.;Fingerle-Rowson, G.;Fink A-M.;et al. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). (Abstract). Blood 2008; 112:325.
46. Dass, S.; Bowman, S. J.; Vital, E. M.; Ikeda, K.; Pease, C. T.; Hamburger, J.; Richards, A.; Rauz, S.; Emery, P. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis, 2008, 67, 1541-1544.
47. Smolen, J. S.; Keystone, E. C.; Emery, P.; Breedveld, F. C.; Betteridge, N.; Burmester, G. R.; Dougados, M.; Ferraccioli, G.; Jaeger, U.; Klareskog, L.; Kvien, T. K.; Martin-Mola, E.; Pavelka, K. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis, 2007, 66, 143-150.
48. Stone, J. H.; Merkel, P. A.; Spiera, R.; Seo, P.; Langford, C. A.; Hoffman, G. S.; Kallenberg, C. G.; St Clair, E. W.; Turkiewicz, A.; Tchao, N. K.; Webber, L.; Ding, L.; Sejismundo, L. P.; Mieras, K.; Weitzenkamp, D.; Ikle, D.; Seyfert-Margolis, V.; Mueller, M.; Brunetta, P.; Allen, N. B.; Fervenza, F. C.; Geetha, D.; Keogh, K. A.; Kissin, E. Y.; Monach, P. A.; Peikert, T.; Stegeman, C.; Ytterberg, S. R.; Specks, U. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 2010, 363, 221-232.
49. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, N.Y, 1987, 235, 177-182.
50. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med, 2000, 6, 443-446.
51. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. The New England journal of medicine, 2007, 357, 39-51.
52. Bang, Y. J.; Van Cutsem, E.; Feyereislova, A.; Chung, H. C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T.; Aprile, G.; Kulikov, E.; Hill, J.; Lehle, M.; Ruschoff, J.; Kang, Y. K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376, 687-697.
53. Reynolds, N. A.; Wagstaff, A. J. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs, 2004, 64, 109-118; discussion 119-121.
54. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med, 2004, 351, 337-345.
55. Iqbal, S.; Lenz, H. J. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol, 2004, 54 Suppl 1, S32-39.
56. Folprecht, G.; Lutz, M. P.; Schoffski, P.; Seufferlein, T.; Nolting, A.; Pollert, P.; Kohne, C. H. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol, 2006, 17, 450-456.
57. Van Cutsem, E.;Nowacki, M.;Lang, I.;Cascinu, S.;Shchepotin, I.;Maurel, J.;Rougier, P.;Cunningham, D.;Nippgen, J.;Köhne, C. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4000.
58. Figg, W. D.; Kruger, E. A.; Price, D. K.; Kim, S.; Dahut, W. D. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs, 2002, 20, 183-194.
59. Berlin, J. D. Targeting vascular endothelial growth factor in colorectal cancer. Oncology (Williston Park), 2002, 16, 13-15.
60. Mordenti, J.; Thomsen, K.; Licko, V.; Chen, H.; Meng, Y. G.; Ferrara, N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol, 1999, 27, 14-21.
61. Chen, H. X.; Gore-Langton, R. E.; Cheson, B. D. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park), 2001, 15, 1017, 1020, 1023-1016.
62. Gordon, M. S.; Margolin, K.; Talpaz, M.; Sledge, G. W., Jr.; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 2001, 19, 843-850.
63. Hoeben, A.; Landuyt, B.; Highley, M. S.; Wildiers, H.; Van Oosterom, A. T.; De Bruijn, E. A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev, 2004, 56, 549-580.
64. Moore, J. M.; Patapoff, T. W.; Cromwell, M. E. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry, 1999, 38, 13960-13967.
65. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350, 2335-2342.
66. Friedman, H. S.; Prados, M. D.; Wen, P. Y.; Mikkelsen, T.; Schiff, D.; Abrey, L. E.; Yung, W. K.; Paleologos, N.; Nicholas, M. K.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol, 2009, 27, 4733-4740.
67. Rini, B. I.; Halabi, S.; Rosenberg, J. E.; Stadler, W. M.; Vaena, D. A.; Archer, L.; Atkins, J. N.; Picus, J.; Czaykowski, P.; Dutcher, J.; Small, E. J. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol, 2010, 28, 2137-2143.
68. Escudier, B.; Bellmunt, J.; Negrier, S.; Bajetta, E.; Melichar, B.; Bracarda, S.; Ravaud, A.; Golding, S.; Jethwa, S.; Sneller, V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol, 2010, 28, 2144-2150.
69. Gawronski, M.; Park, J. T.; Magee, A. S.; Conrad, H. Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle x-ray scattering. Biopolymers, 1999, 50, 569-578.
70. Wasser, S. P.; Weis, A. L. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol, 1999, 19, 65-96.
71. Yan, J.; Allendorf, D. J.; Brandley, B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther, 2005, 5, 691-702.
72. Li, B.; Cramer, D.; Wagner, S.; Hansen, R.; King, C.; Kakar, S.; Ding, C.; Yan, J. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88-and Syk kinase-dependent pathways. Clin Immunol, 2007, 124, 170-181.
73. Goodridge, H. S.; Reyes, C. N.; Becker, C. A.; Katsumoto, T. R.; Ma, J.; Wolf, A. J.; Bose, N.; Chan, A. S.; Magee, A. S.; Danielson, M. E.; Weiss, A.; Vasilakos, J. P.; Underhill, D. M. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature, 2011, 472, 471-475.
74. Qi, C.; Cai, Y.; Gunn, L.; Ding, C.; Li, B.; Kloecker, G.; Qian, K.; Vasilakos, J.; Saijo, S.; Iwakura, Y.; Yannelli, J. R.; Yan, J. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived {beta}-glucans. Blood, 2011, 117, 6825-6836.
75. Liu, J.; Gunn, L.; Hansen, R.; Yan, J. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp Mol Pathol, 2009, 86, 208-214.
76. Li, B.; Allendorf, D. J.; Hansen, R.; Marroquin, J.; Ding, C.; Cramer, D. E.; Yan, J. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol, 2006, 177, 1661-1669.
77. Ooi, V. E.; Liu, F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem, 2000, 7, 715-729.
78. Di Luzio, N. R.; McNamee, R.; Browder, W. I.; Williams, D. Glucan:inhibition of tumor growth and enhancement of survival in four syngeneic murine tumor models. Cancer Treat Rep, 1978, 62, 1857-1866.
79. Di Luzio, N. R.; Williams, D. L.; McNamee, R. B.; Edwards, B. F.; Kitahama, A. Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Int J Cancer, 1979, 24, 773-779.
80. Sherwood, E. R.; Williams, D. L.; McNamee, R. B.; Jones, E. L.; Browder, I. W.; Di Luzio, N. R. In vitro tumoricidal activity of resting and glucanactivated Kupffer cells. J Leukoc Biol, 1987, 42, 69-75.
81. Sherwood, E. R.; Williams, D. L.; McNamee, R. B.; Jones, E. L.; Browder, I. W.; Di Luzio, N. R. Enhancement of interleukin-1 and interleukin-2 production by soluble glucan. International journal of immunopharmacology, 1987, 9, 261-267.
82. Ross, G. D.; Cain, J. A.; Myones, B. L.; Newman, S. L.; Lachmann, P. J. Specificity of membrane complement receptor type three (CR3) for betaglucans. Complement, 1987, 4, 61-74.
83. Ross, G. D.; Vetvicka, V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol, 1993, 92, 181-184.
84. Sze, D. M.; Chan, G. C. Supplements for immune enhancement in hematologic malignancies. Hematology Am Soc Hematol Educ Program, 2009, 313-319.
85. Kidd, P. M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev, 2000, 5, 4-27.
86. Nakazato, H.; Koike, A.; Saji, S.; Ogawa, N.; Sakamoto, J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet, 1994, 343, 1122-1126.
87. Niimoto, M.; Hattori, T.; Tamada, R.; Sugimachi, K.; Inokuchi, K.; Ogawa, N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg, 1988, 18, 681-686.
88. American Cancer Society. Diet and Nutrition: Coriolus Versicolor http:// www.cancer.org/ Treatment/ Treatments and Side Effects/ Complementary and Alternative Medicine/DietandNutrition/coriolus-versicolor.
89. Torisu, M.; Hayashi, Y.; Ishimitsu, T.; Fujimura, T.; Iwasaki, K.; Katano, M.; Yamamoto, H.; Kimura, Y.; Takesue, M.; Kondo, M.; et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother, 1990, 31, 261-268.
90. Mitomi, T.; Tsuchiya, S.; Iijima, N.; Aso, K.; Suzuki, K.; Nishiyama, K.; Amano, T.; Takahashi, T.; Murayama, N.; Oka, H.; et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum, 1992, 35, 123-130.
91. Ohwada, S.; Ikeya, T.; Yokomori, T.; Kusaba, T.; Roppongi, T.; Takahashi, T.; Nakamura, S.; Kakinuma, S.; Iwazaki, S.; Ishikawa, H.; Kawate, S.; Nakajima, T.; Morishita, Y. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. British journal of cancer, 2004, 90, 1003-1010.
92. ©2012 Susan G. Komen for the Cure®. Polysaccharide K (PSK): background http://ww5.komen.org/BreastCancer/PolysaccharideKPSK.html.
93. Liu J, Zhou J. Phase II clinical trial for PSP capsules. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:183-208.
94. Shi, J. PSP for the protection of the tumorous patients during chemotherapy. In: Yang, Q.;Kwok, C. Ed. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993; pp. 271-272.
95. Wu, C.;Wu, J.;Sun, W. The curative effect of Yun Zhi polysaccharopeptide (PSP) on stomach cancer. In: Yang, Q. Ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999; pp. 322-323.
96. Yao W. Prospective randomized trial of radiotherapy plus PSP in the treatment of esophageal carcinoma. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:310-313.
97. Tamayo, M.E.;Cornelio, G.H.;Bautista, J.B.;Flores, M.L.;Kurman, M.R.;Paul, M .M.;Gargano, M.A.;Patchen, M.L. A phase Ib/2, dose-escalating, safety, and efficacy study of imprime PGG, cetuximab and irinotecan in patients with advanced colorectal cancer (CRC). J Clin Oncol 27, 2009 (suppl; abstr e15062)
98. Tamayo, M.E.;Cornelio, G.H.;Bautista, J.B.;Flores, M.L.;Tioleco, P.S.;Kurman, M.R.;Marsh, L.M.;Gargano, M.A.;Patchen, M.L. A phase Ib/II, doseescalating, safety, and efficacy study of imprime PGG and cetuximab in patients with advanced colorectal cancer (CRC). J Clin Oncol 28, 2010 (suppl; abstr e14103)
99. Tamayo, M.E.;Cornelio, G.H.;Bautista, J.B.;Flores, M.L.;Tioleco, P.S.;Kurman, M.R.;Vasilakos, J.;Marsh, L.M.;Gargano, M.A.;Patchen, M.L. PD-0009. Safety and efficacy of imprime PGG plus cetuximab with irinotecan and without irinotecan in patients with advanced colorectal cancer (CRC): a phase 1b/2 study with kras subpopulation analysis ANN ONCOL 21, 2010 (Suppl 6 abstr PD0009)
100. Sobrero, A. F.; Maurel, J.; Fehrenbacher, L.; Scheithauer, W.; Abubakr, Y. A.; Lutz, M. P.; Vega-Villegas, M. E.; Eng, C.; Steinhauer, E. U.; Prausova, J.; Lenz, H. J.; Borg, C.; Middleton, G.; Kroning, H.; Luppi, G.; Kisker, O.; Zubel, A.; Langer, C.; Kopit, J.; Burris, H. A., 3rd EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26, 2311-2319.
101. Tamayo, M.E.;Cornelio, G.H.;Bautista, J.B.;Flores, M.L.;Kurman, M.R.;Paul, M .M.;Gargano, M.A.;Patchen, M.L. A phase Ib/2, dose-escalating, safety, and efficacy study of imprime PGG, cetuximab and irinotecan in patients with advanced colorectal cancer (CRC). J Clin Oncol 27, 2009 (suppl; abstr e15062)
102. Tamayo, M.E.;Cornelio, G.H.;Bautista, J.B.;Flores, M.L.;Tioleco, P.S.;Kurman, M.R.;Marsh, L.M.;Gargano, M.A.;Patchen, M.L. A phase Ib/II, doseescalating, safety, and efficacy study of imprime PGG and cetuximab in patients with advanced colorectal cancer (CRC). J Clin Oncol 28, 2010 (suppl; abstr e14103)
103. NIH ClinicalTrials.gov search of imprime PGG http://clinicaltrials.gov/ ct2/results?term=imprime+PGG.
104. Kantoff, P. W.; Higano, C. S.; Shore, N. D.; Berger, E. R.; Small, E. J.; Penson, D. F.; Redfern, C. H.; Ferrari, A. C.; Dreicer, R.; Sims, R. B.; Xu, Y.; Frohlich, M. W.; Schellhammer, P. F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010, 363, 411-422.
105. Lin, H.; She, Y. H.; Cassileth, B. R.; Sirotnak, F.; Cunningham Rundles, S. Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int Immunopharmacol, 2004, 4, 91-99.
106. Cramer, D. E.; Allendorf, D. J.; Baran, J. T.; Hansen, R.; Marroquin, J.; Li, B.; Ratajczak, J.; Ratajczak, M. Z.; Yan, J. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood, 2006, 107, 835-840.